InterMune to Present at Thomas Weisel Partners Healthcare Conference

Friday, August 29, 2008 General News J E 4
BRISBANE, Calif., Aug. 29 InterMune, Inc.(Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO andPresident of InterMune, will present at the Thomas Weisel Partners HealthcareConference in Boston on September 4, 2008 at 10:55 a.m. EDT.

To access a live audio webcast of the presentation, investors and otherinterested parties may log on to the investor relations page of InterMune'scorporate website at The company recommends loggingon to the site 15 minutes prior to the start of the presentation in order toregister or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.InterMune has a research and development portfolio addressing idiopathicpulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. Thepulmonology portfolio includes the Phase 3 program, CAPACITY, which isevaluating pirfenidone for the treatment of patients with IPF and a researchprogram focused on small molecules for pulmonary disease. The hepatologyportfolio includes the HCV protease inhibitor compound ITMN-191 (referred toas R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitorresearch program, and a research program evaluating a new target inhepatology. For additional information about InterMune and its R&D pipeline,please visit

SOURCE InterMune, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Deer Farm Industry in Michigan Issues Statement on...
Preliminary Report of American Biotech Labs HIV St...